Skip to main content

ESTUDIO EN PROFUNDIDAD DEL CANALOSOMA CARDIACO DE KV1.5

SAF2016-75021-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

In-depth study of the interaction, sensitivity, and gating modulation by PUFAs on K+ channels; interaction and new targets

  • Moreno, Cristina
  • Cruz, Alicia de la
  • Valenzuela, Carmen
Voltage gated potassium channels (KV) are membrane proteins that allow selective flow of K ions in a voltage-dependent manner. These channels play an important role in several excitable cells as neurons, cardiomyocytes, and vascular smooth muscle. Over the last 20 years, it has been shown that omega-3 polyunsaturated fatty acids (PUFAs) enhance or decrease the activity of several cardiac KV channels. PUFAs-dependent modulation of potassium ion channels has been reported to be cardioprotective. However, the precise cellular mechanism underlying the cardiovascular benefits remained unclear in part because new PUFAs targets and signaling pathways continue being discovered. In this review, we will focus on recent data available concerning the following aspects of the K channel modulation by PUFAs: (i) the exact residues involved in PUFAs-K channels interaction; (ii) the structural PUFAs determinants important for their effects on K channels; (iii) the mechanism of the gating modulation of KV channels and, finally, (iv) the PUFAs modulation of a few new targets present in smooth muscle cells (SMC), K1.1, KP, and KATP channels, involved in vascular relaxation., This work was supported by SAF2013-45800-R, SAF2016-75021-R, FIS RIC-RD12/0042/0019, and FIS CIBER CB/11/00222 Grants. RIC and CIBER are funded by the Instituto de Salud Carlos III. The cost of this publication was paid in part by funds from the European Fund for Economic and Regional Development. AdlC holds a CSIC contract., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fludarabine inhibits KV1.3 currents in human B lymphocytes

  • Cruz, Alicia de la
  • Vera-Zambrano, Alba
  • Peraza, Diego A.
  • Valenzuela, Carmen
  • Zapata, Juan M.
  • Pérez-Chacón, Gema
  • González, Teresa
Fludarabine (F-ara-A) is a purine analog commonly used in the treatment of indolent B cell malignancies that interferes with different aspects of DNA and RNA synthesis. KV1.3 K+ channels are membrane proteins involved in the maintenance of K+ homeostasis and the resting potential of the cell, thus controlling signaling events, proliferation and apoptosis in lymphocytes. Here we show that F-ara-A inhibits KV currents in human B lymphocytes. Our data indicate that KV1.3 is expressed in both BL2 and Dana B cell lines, although total KV1.3 levels were higher in BL2 than in Dana cells. However, KV currents in the plasma membrane were similar in both cell lines and were abrogated by the specific KV1.3 channel inhibitor PAP-1, indicating that KV1.3 accounts for most of the KV currents in these cell lines. F-ara-A, at a concentration (3.5 μM) similar to that achieved in the plasma of fludarabine phosphate-treated patients (3 μM), inhibited KV1.3 currents by 61 ± 6.3% and 52.3 ± 6.3% in BL2 and Dana B cells, respectively. The inhibitory effect of F-ara-A was concentration-dependent and showed an IC50 value of 0.36 ± 0.04 μM and a nH value of 1.07 ± 0.15 in BL2 cells and 0.34 ± 0.13 μM (IC50) and 0.77 ± 0.11 (nH) in Dana cells. F-ara-A inhibition of plasma membrane KV1.3 was observed irrespective of its cytotoxic effect on the cells, BL2 cells being sensitive and Dana cells resistant to F-ara-A cytotoxicity. Interestingly, PAP-1, at concentrations as high as 10 μM, did not affect the viability of BL2 and Dana cells, indicating that blockage of KV1.3 in these cells is not toxic. Finally, F-ara-A had no effect on ectopically expressed KV1.3 channels, suggesting an indirect mechanism of current inhibition. In summary, our results describe the inhibitory effect of F-ara-A on the activity of KV1.3 channel. Although KV1.3 inhibition is not sufficient to induce cell death, further research is needed to determine whether it might still contribute to F-ara-A cytotoxicity in sensitive cells or be accountable for some of the clinical side effects of the drug., This study was supported by MINECO (SAF2013-45800-R, SAF2016-75021-R, RD12/0042/0019, CB/11/00222) and ISCIII (PI12/01135 and PI16/00895). The cost of this publication was paid in part by funds from the European Fund for Economic and Regional Development (FEDER). TG is supported by the Ramón y Cajal Program., Peer reviewed, Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

D242N, a KV7.1 LQTS mutation uncovers a key residue for IKs voltage dependence

  • Moreno, Cristina
  • Oliveras, Anna
  • Bartolucci, Chiara
  • Muñoz, Carmen
  • Cruz, Alicia de la
  • Peraza, Diego A.
  • Gimeno, Juan R.
  • Martín-Martínez, Mercedes
  • Severi, Stefano
  • Felipe, Antonio
  • Lambiase, Pier
  • González, Teresa
  • Valenzuela, Carmen
Corrigendum to Supplemental Material: 'D242N, a KV7.1 LQTS mutation uncovers a key residue for IKs voltage dependence' [Journal of Molecular and Cellular Cardiology, Volume 110, September 2017, Pages 61-69]. [J Mol Cell Cardiol. 2019]., KV7.1 and KCNE1 co-assemble to give rise to the IKs current, one of the most important repolarizing currents of the cardiac action potential. Its relevance is underscored by the identification of > 500 mutations in KV7.1 and, at least, 36 in KCNE1, that cause Long QT Syndrome (LQTS). The aim of this study was to characterize the biophysical and cellular consequences of the D242N KV7.1 mutation associated with the LQTS. The mutation is located in the S4 transmembrane segment, within the voltage sensor of the KV7.1 channel, disrupting the conserved charge balance of this region. Perforated patch-clamp experiments show that, unexpectedly, the mutation did not disrupt the voltage-dependent activation but it removed the inactivation and slowed the activation kinetics of D242N KV7.1 channels. Biotinylation of cell-surface protein and co-immunoprecipitation experiments revealed that neither plasma membrane targeting nor co-assembly between KV7.1 and KCNE1 was altered by the mutation. However, the association of D242N KV7.1 with KCNE1 strongly shifted the voltage dependence of activation to more depolarized potentials (+ 50 mV), hindering IKs current at physiologically relevant membrane potentials. Both functional and computational analysis suggest that the clinical phenotype of the LQTS patients carrying the D242N mutation is due to impaired action potential adaptation to exercise and, in particular, to increase in heart rate. Moreover, our data identify D242 aminoacidic position as a potential residue involved in the KCNE1-mediated regulation of the voltage dependence of activation of the KV7.1 channel., This work was supported by Ministerio de Economía y Competitividad (MINECO) Spain (SAF2013-45800-R, SAF2016-75021-R, BFU2014-54928-R, RIC RD12/0042/0019 and CIBER CB/11/00222). PDL is supported by UCLH Biomedicine NIHR. The cost of this publication was paid in part by funds from the European Fund for Economic and Regional Development. TG holds a Ramón y Cajal contract. AdlC and DAP held CSIC contracts., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Activation of Kv7 channels as a novel mechanism for NO/cGMP‐induced pulmonary vasodilation

  • Mondéjar‐Parreño, Gema
  • Moral‐Sanz, Javier
  • Barreira, Bianca
  • Cruz, Alicia de la
  • González, Teresa
  • Callejo, Maria
  • Esquivel‐Ruiz, Sergio
  • Morales‐Cano, Daniel
  • Moreno Capellán, Laura
  • Valenzuela, Carmen
  • Pérez-Vizcaíno, Francisco
  • Cogolludo, Angel
[Background and Purpose]: The NO/cGMP pathway represents a major physiological signalling controlling tone in pulmonary arteries (PA), and drugs activating this pathway are used to treat pulmonary arterial hypertension. Kv channels expressed in PA smooth muscle cells (PASMCs) are key determinants of vascular tone. We aimed to analyse the contribution of Kv1.5 and Kv7 channels in the electrophysiological and vasodilating effects evoked by NO donors and the GC stimulator riociguat in PA., [Experimental Approach]: Kv currents were recorded in isolated rat PASMCs using the patch‐clamp technique. Vascular reactivity was assessed in a wire myograph., [Key Results]: The NO donors diethylamine NONOate diethylammonium (DEA‐NO) and sodium nitroprusside hyperpolarized the membrane potential and induced a bimodal effect on Kv currents (augmenting the current between −40 and −10 mV and decreasing it at more depolarized potentials). The hyperpolarization and the enhancement of the current were suppressed by Kv7 channel inhibitors and by the GC inhibitor ODQ but preserved when Kv1.5 channels were inhibited. Additionally, DEA‐NO enhanced Kv7.5 currents in COS7 cells expressing the KCNQ5 gene. Riociguat increased Kv currents at all potentials ≥−40 mV and induced membrane hyperpolarization. Both effects were prevented by Kv7 inhibition. Likewise, PA relaxation induced by NO donors and riociguat was attenuated by Kv7 inhibitors., [Conclusions and Implications]: NO donors and riociguat enhance Kv7 currents, leading to PASMC hyperpolarization. This mechanism contributes to NO/cGMP‐induced PA vasodilation. Our study identifies Kv7 channels as a novel mechanism of action of vasodilator drugs used in the treatment of pulmonary arterial hypertension., This work was funded by Ministerio de Economía y Competitividad grants (SAF2016‐77222R to F.P.‐V. and A.C. and SAF2016‐75021‐R to C.V. and T.G.), the Cardiovascular Medical Research and Education Fund (A.C.), Fundación Contra la Hipertensión Pulmonar‐EMPATHY, Comunidad de Madrid (B2017/BMD‐3727 to A.C. and L.M.), and Instituto de Salud Carlos III (PI15/01100 to L.M. and CB/11/00222 to C.V.) with funds from the European Union (Fondo Europeo de Desarrollo Regional FEDER). G.M.‐P., M.C., and S.E.‐R. are supported by CIBERES, Universidad Complutense and FPU grants., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Diferential efect of Androctonus australis hector venom components on macrophage KV channels: electrophysiological characterization

  • Khemili, Dalila
  • Valenzuela, Carmen
  • Laraba‑Djebari, Fatima
  • Hammoudi‑Triki, Djelila
Neurotoxins of scorpion venoms modulate ion channels. Voltage-gated potassium (KV) channels regulate the membrane potential and are involved in the activation and proliferation of immune cells. Macrophages are key components of the inflammatory response induced by scorpion venom. The present study was undertaken to investigate the effect of Androctonus australis hector (Aah) venom on KV channels in murine resident peritoneal macrophages. The cytotoxicity of the venom was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) -based assay and electrophysiological recordings were performed using the whole-cell patch clamp technique. High doses of Aah venom (50, 125, 250 and 500 µg/ml) significantly decreased cell viability, while concentrations of 0.1-25 µg/ml were not cytotoxic towards peritoneal macrophages. Electrophysiological data revealed a differential block of KV current between resting and LPS-activated macrophages. Aah venom significantly reduced KV current amplitude by 62.5 ± 4.78% (n = 8, p < 0.05), reduced the use-dependent decay of the current, decreased the degree of inactivation and decelerated the inactivation process of KV current in LPS-activated macrophages. Unlike cloned KV1.5 channels, Aah venom exerted a similar blocking effect on KV1.3 compared to KV current in LPS-activated macrophages, along with a hyperpolarizing shift in the voltage dependence of KV1.3 inactivation, indicating a direct mechanism of current inhibition by targeting KV1.3 subunits. The obtained results, demonstrating that Aah venom differentially targets KV channels in macrophages, suggest differential outcomes for their inhibitions, and that further investigations of scorpion venom immunomodulatory potential are required., Ion channels laboratory (leaded by Dr. Carmen Valenzuela) received support from Ministerio de Economía, Industria y Competitividad (MINEICO) of Spain: SAF2013-45800-R, SAF2016-75021-R, CIBERCV CB/11/00222 and the European Regional Development Funds (FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Identification of IQM-266, a novel DREAM ligand that modulates KV4 currents

  • Peraza, Diego A.
  • Cercós, Pilar
  • Miaja, Pablo
  • Merinero, Yaiza G.
  • Lagartera, Laura
  • Socuéllamos, Paula G.
  • Izquierdo García, Carolina
  • Sánchez, Sara A.
  • López-Hurtado, Alejandro
  • Martín-Martínez, Mercedes
  • Olivos-Oré, Luis Alcides
  • Naranjo, José Ramón
  • Artalejo, Antonio R.
  • Gutiérrez-Rodríguez, Marta
  • Valenzuela, Carmen
Downstream Regulatory Element Antagonist Modulator (DREAM)/KChIP3/calsenilin is a neuronal calcium sensor (NCS) with multiple functions, including the regulation of A-type outward potassium currents (I A). This effect is mediated by the interaction between DREAM and KV4 potassium channels and it has been shown that small molecules that bind to DREAM modify channel function. A-type outward potassium current (I A) is responsible of the fast repolarization of neuron action potentials and frequency of firing. Using surface plasmon resonance (SPR) assays and electrophysiological recordings of KV4.3/DREAM channels, we have identified IQM-266 as a DREAM ligand. IQM-266 inhibited the KV4.3/DREAM current in a concentration-, voltage-, and time-dependent-manner. By decreasing the peak current and slowing the inactivation kinetics, IQM-266 led to an increase in the transmembrane charge ( QKV4.3/DREAM ) at a certain range of concentrations. The slowing of the recovery process and the increase of the inactivation from the closed-state inactivation degree are consistent with a preferential binding of IQM-266 to a pre-activated closed state of KV4.3/DREAM channels. Finally, in rat dorsal root ganglion neurons, IQM-266 inhibited the peak amplitude and slowed the inactivation of I A. Overall, the results presented here identify IQM-266 as a new chemical tool that might allow a better understanding of DREAM physiological role as well as modulation of neuronal I A in pathological processes., PC was the recipient of a postgraduate FPI fellowship from the Spanish Ministry of Economy, Industry and Competitivity (MINECO). This work was funded by the Spanish Ministry of Economy, Industry and Competitivity (Ministerio de Economía y Competitividad; AEI-FEDER, EU grants): SAF2012-32209 and BFU2015-67284-R (to MG-R), SAF2014-53412-R and SAF2017- 89554-R (to JN), SAF2013-45800-R, SAF2016-75021-R (to CV) and SAF2015-66275-C2-2-R (to MM-M); Universidad Complutense de Madrid (UCM) grant: PR75/18-21593 (to AA); the Instituto de Salud Carlos III CIBERNED and CIBERCV programs (to JN and to CV, respectively) and the Madrid regional government/Neurodegmodels (to JN); Consejo Superior de Investigaciones Científicas (CSIC) grants: PIE 201820E104 (to CV) and 201880E109 (to MG-R and MM-M)., We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeting the neuronal calcium sensor DREAM with small-molecules for Huntington’s disease treatment

  • López-Hurtado, Alejandro
  • Peraza, Diego A.
  • Cercós, Pilar
  • Lagartera, Laura
  • González Pérez, Paz
  • Dopazo, Xose M.
  • Herranz, Rosario
  • González, Teresa
  • Martín-Martínez, Mercedes
  • Mellström, Britt
  • Naranjo, José Ramón
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
DREAM, a neuronal calcium sensor protein, has multiple cellular roles including the regulation of Ca2+ and protein homeostasis. We recently showed that reduced DREAM expression or blockade of DREAM activity by repaglinide is neuroprotective in Huntington's disease (HD). Here we used structure-based drug design to guide the identification of IQM-PC330, which was more potent and had longer lasting effects than repaglinide to inhibit DREAM in cellular and in vivo HD models. We disclosed and validated an unexplored ligand binding site, showing Tyr118 and Tyr130 as critical residues for binding and modulation of DREAM activity. IQM-PC330 binding de-repressed c-fos gene expression, silenced the DREAM effect on KV4.3 channel gating and blocked the ATF6/DREAM interaction. Our results validate DREAM as a valuable target and propose more effective molecules for HD treatment., PC was the recipient of a postgraduate FPI fellowship from the Spanish Ministry de Economy, Industry and Competitivity (MINECO). P.C. also thanks the Spanish Society of Therapeutic Chemistry (SEQT) for a Jassen-Cilag Award for young researchers (XVIII Edition, 2016). T.G. holds a Ramón y Cajal contract. D.A.P. holds a CSIC contract. This work was funded by the Spanish Ministery of Economy, Industry and Competitivity (AEI-FEDER, EU grants): BFU2015-67284-R (to M.G.R., R.H.), SAF2017-89554-R (to J.R.N.), SAF2016-75021-R (to C.V.) and SAF2015-66275-C2-2-R (to M.M.M.); the Instituto de Salud Carlos III CIBERNED and CIBERCV programs (to J.R.N. and to C.V., respectively) and the Madrid regional government/Neurodegmodels (to J.R.N.); CSIC grant PIE201880E109 (to M.G.R., R.H. and M.M.M.) and PIE201820E104 (to C.V.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The unconventional biogenesis of Kv7.1-KCNE1 complexes

  • Oliveras, Anna
  • Serrano-Novillo, Clara
  • Moreno, Cristina
  • Cruz, Alicia de la
  • Valenzuela, Carmen
  • Soeller, Christian
  • Comes, Núria
  • Felipe, Antonio
The potassium channel Kv7.1 associates with the KCNE1 regulatory subunit to trigger cardiac IKs currents. Although the Kv7.1/KCNE1 complex has received much attention, the subcellular compartment hosting the assembly is the subject of ongoing debate. Evidence suggests that the complex forms either earlier in the endoplasmic reticulum or directly at the plasma membrane. Kv7.1 and KCNE1 mutations, responsible for long QT syndromes, impair association and traffic, thereby altering IKs currents. We found that Kv7.1 and KCNE1 do not assemble in the first stages of their biogenesis. Data support an unconventional secretory pathway for Kv7.1-KCNE1 that bypasses Golgi. This route targets channels to endoplasmic reticulum–plasma membrane junctions, where Kv7.1-KCNE1 assemble. This mechanism helps to resolve the ongoing controversy about the subcellular compartment hosting the association. Our results also provide new insights into IKs channel localization at endoplasmic reticulum–plasma membrane junctions, highlighting an alternative anterograde trafficking mechanism for oligomeric ion channels., This work was supported by the Ministerio de Economia y Competitividad (MINECO, Spain) (grants BFU2014-54928-R and BFU2017-87104-R to A.F. and SAF2016-75021-R to C.V.), Fondo Europeo de Desarrollo Regional (FEDER), the Instituto de Salud Carlos III CIBERCV program (to C.V.), and CSIC grant PIE201820E104 (to C.V.). A.O. and C.S.-N. hold fellowships from the MINECO., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pharmacological Approaches for the Modulation of the Potassium Channel KV4.x and KChIPs

  • Cercós, Pilar
  • Peraza, Diego A.
  • Benito-Bueno, Ángela de
  • Socuéllamos, Paula G.
  • Aziz-Nignan, A.
  • Arrechaga-Estévez, D.
  • Beato, E.
  • Peña-Acevedo, E.
  • Albert, Armando
  • Martín-Martínez, Mercedes
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
Ion channels are macromolecular complexes present in the plasma membrane and intracellular organelles of cells. Dysfunction of ion channels results in a group of disorders named channelopathies, which represent an extraordinary challenge for study and treatment. In this review, we will focus on voltage-gated potassium channels (KV), specifically on the KV4-family. The activation of these channels generates outward currents operating at subthreshold membrane potentials as recorded from myocardial cells (ITO, transient outward current) and from the somata of hippocampal neurons (ISA). In the heart, KV4 dysfunctions are related to Brugada syndrome, atrial fibrillation, hypertrophy, and heart failure. In hippocampus, KV4.x channelopathies are linked to schizophrenia, epilepsy, and Alzheimer’s disease. KV4.x channels need to assemble with other accessory subunits () to fully reproduce the ITO and ISA currents. Subunits affect channel gating and/or the traffic to the plasma membrane, and their dysfunctions may influence channel pharmacology. Among KV4 regulatory subunits, this review aims to analyze the KV4/KChIPs interaction and the effect of small molecule KChIP ligands in the A-type currents generated by the modulation of the KV4/KChIP channel complex. Knowledge gained from structural and functional studies using activators or inhibitors of the potassium current mediated by KV4/KChIPs will better help understand the underlying mechanism involving KV4-mediated-channelopathies, establishing the foundations for drug discovery, and hence their treatments., This research was funded by Ministerio de Ciencia e Innovación (MICIU) Spain SAF2016- 75021-R and PID2019-104366RB-C21 (to CV), RTI2018-097189-B-C22 (to MMM), PID2019-104366RBC22 (to MG-R); the Instituto de Salud Carlos III CIBERCV program CB/11/00222 (to CV); and the Consejo Superior de Investigaciones Científicas grants: PIE 201820E104, 2019AEP148 (to CV), and 201880E109 (to MMM and MG-R). The cost of this publication was paid in part by funds from the European Fund for Economic and Regional Development (FEDER). PC held a postgraduate FPI fellowship from the Spanish Ministry of Economy, Industry, and Competitivity (MINECO). DAP held CSIC contracts. AdB-B holds a MICIU predoctoral contract (BES-2017-080184). PGS holds a MICIU predoctoral contract FPU2017/02731. AAN, DAE, EB, and EPA were sponsored by CUNY Research Scholars Program (CRSP) and Collegiate Science Technology Entry Program (CSTEP). YR is grateful to the Hostos Office of Academic Affairs for providing travel awards and the OpenEye Scientific Software for providing free academic licenses. We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Kv1.3 channels are novel determinants of macrophage-dependent endothelial dysfunction in angiotensin II-induced hypertension in mice

  • Olivencia, Miguel A.
  • Martínez-Casales, Marta
  • Peraza, Diego A.
  • García-Redondo, Ana B.
  • Mondéjar‐Parreño, Gema
  • Hernanz, Raquel
  • Salaices, Mercedes
  • Cogolludo, Angel
  • Pennington, Michael W.
  • Valenzuela, Carmen
  • Briones, Ana M.
[Background and Purpose]: KV1.3 channels are expressed in vascular smooth muscle cells (VSMCs), where they contribute to proliferation rather than contraction and participate in vascular remodelling. KV1.3 channels are also expressed in macrophages, where they assemble with KV1.5 channels (KV1.3/KV1.5), whose activation generates a KV current. In macrophages, the KV1.3/KV1.5 ratio is increased by classical activation (M1). Whether these channels are involved in angiotensin II (AngII)-induced vascular remodelling, and whether they can modulate the macrophage phenotype in hypertension, remains unknown. We characterized the role of KV1.3 channels in vascular damage in hypertension., [Experimental Approach]: We used AngII-infused mice treated with two selective KV1.3 channel inhibitors (HsTX[R14A] and [EWSS]ShK). Vascular function and structure were measured using wire and pressure myography, respectively. VSMC and macrophage electrophysiology were studied using the patch-clamp technique; gene expression was analysed using RT-PCR., [Key Results]: AngII increased KV1.3 channel expression in mice aorta and peritoneal macrophages which was abolished by HsTX[R14A] treatment. KV1.3 inhibition did not prevent hypertension, vascular remodelling, or stiffness but corrected AngII-induced macrophage infiltration and endothelial dysfunction in the small mesenteric arteries and/or aorta, via a mechanism independent of electrophysiological changes in VSMCs. AngII modified the electrophysiological properties of peritoneal macrophages, indicating an M1-like activated state, with enhanced expression of proinflammatory cytokines that induced endothelial dysfunction. These effects were prevented by KV1.3 blockade., [Conclusions and Implications]: We unravelled a new role for KV1.3 channels in the macrophage-dependent endothelial dysfunction induced by AngII in mice which might be due to modulation of macrophage phenotype., This work was funded by the Ministerio de Economía y Competitividad; AEI-FEDER, EU grants: SAF2016-75021-R and PID2019-104366RB-C21 (to C.V.), SAF2016-80305-P (to A.M.B. and M.S.), and SAF2016-77222-R (to A.C.); Instituto de Salud Carlos III CIBERCV program: CB16/11/00286 (to M.S.) and CB/11/00222 (to C.V.); Consejo Superior de Investigaciones Científicas grants: PIE 201820E104 and 2019AEP148 (to C.V.) and Comunidad de Madrid grant: B2017/BMD-3676-AORTASANA (to M.S.) and B2017/BMD-3727 (to A.C.) with funds co-financed by ERDF (FEDER) Funds from the European Commission, “A way of making Europe”; and Comunidad de Madrid-Universidad Autónoma de Madrid grant: SI1-PJ1-2019-00321 (to A.B.G.-R.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Kv1.5-Kvb1.3 Recycling is PKC-Dependent

  • Macías, Álvaro
  • Cruz, Alicia de la
  • Peraza, Diego A.
  • Benito-Bueno, Ángela de
  • González, Teresa
  • Valenzuela, Carmen
© 2021 by the authors., KV1.5 channel function is modified by different regulatory subunits. KVβ1.3 subunits assemble with KV1.5 channels and induce a fast and incomplete inactivation. Inhibition of PKC abolishes the KVβ1.3-induced fast inactivation, decreases the amplitude of the current KV1.5–KVβ1.3 and modifies their pharmacology likely due to changes in the traffic of KV1.5–KVβ1.3 channels in a PKC-dependent manner. In order to analyze this hypothesis, HEK293 cells were transfected with KV1.5–KVβ1.3 channels, and currents were recorded by whole-cell configuration of the patch-clamp technique. The presence of KV1.5 in the membrane was analyzed by biotinylation techniques, live cell imaging and confocal microscopy approaches. PKC inhibition resulted in a decrease of 33 ± 7% of channels in the cell surface due to reduced recycling to the plasma membrane, as was confirmed by confocal microscopy. Live cell imaging indicated that PKC inhibition almost abolished the recycling of the KV1.5–KVβ1.3 channels, generating an accumulation of channels into the cytoplasm. All these results suggest that the trafficking regulation of KV1.5–KVβ1.3 channels is dependent on phosphorylation by PKC and, therefore, they could represent a clinically relevant issue, mainly in those diseases that exhibit modifications in PKC activity., This research was funded by Ministerio de Ciencia e Innovación (MICINN) Spain SAF2016-75021-R and PID2019-104366RB-C21 (to C.V. and T.G.), the Instituto de Salud Carlos III CIBERCV program CB/11/00222 (to C.V.), and the Consejo Superior de Investigaciones Científicas grants: PIE201820E104 and 2019AEP148 (to C.V.). The cost of this publication was paid in part by funds from the European Fund for Economic and Regional Development (FEDER). A.M. holds a postdoctoral contract at CNIC. A.d.l.C. and D.A.P. held CSIC contracts. A.d.B.-B. holds an MICINN predoctoral contract (BES-2017-080184).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Trabectedin modulates macrophage polarization in the tumor-microenvironment. Role of Kv1.3 and Kv1.5 channels

  • Peraza, Diego A.
  • Povo-Retana, Adrián
  • Mojena, Marina
  • García-Redondo, Ana B.
  • Avilés, Pablo
  • Boscá, Lisardo
  • Valenzuela, Carmen
Immune cells have an important role in the tumor-microenvironment. Macrophages may tune the immune response toward inflammatory or tolerance pathways. Tumor-associated macrophages (TAM) have a string of immunosuppressive functions and they are considered a therapeutic target in cancer. This study aimed to analyze the effects of trabectedin, an antitumor agent, on the tumor-microenvironment through the characterization of the electrophysiological and molecular phenotype of macrophages. Experiments were performed using the whole-cell configuration of the patch-clamp technique in resident peritoneal mouse macrophages. Trabectedin does not directly interact with KV1.5 and KV1.3 channels, but their treatment (16 h) with sub-cytotoxic concentrations of trabectedin increased their KV current due to an upregulation of KV1.3 channels. In vitro generated TAM (TAMiv) exhibited an M2-like phenotype. TAMiv generated a small KV current and express high levels of M2 markers. K+ current from TAMs isolated from tumors generated in mice is a mixture of KV and KCa, and in TAM isolated from tumors generated in trabectedin-treated mice, the current is mostly driven by KCa. We conclude that the antitumor capacity of trabectedin is not only due to its effects on tumor cells, but also to the modulation of the tumor microenvironment, due, at least in part, to the modulation of the expression of different macrophage ion channels., This research was funded by AEI, Grants SAF2016-75021-R (to CV) funded by MICIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”; Grants PID2019-104366RB-C21 (to CV) and PID2020-113238RB-I00 (to L.B.) funded by MCIN/AEI/10.13039/501100011033; by CIBERCV, Grant CB/11/00222 funded by Instituto de Salud Carlos III (to LB and CV) co-financed by the European Development Regional Fund “A Way to Achieve Europe”); Comunidad de Madrid Programa Biociencias (P2022-BMD-7223); by CSIC Grants PIE201820E104 and 2019AEP148 (to CV). This research was partially funded by a grant from a PharmaMar S.A. Grant., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Resolvin D2 Attenuates Cardiovascular Damage in Angiotensin II-Induced Hypertension

  • Díaz del Campo, Lucía S.
  • García-Redondo, Ana B.
  • Rodríguez, Cristina
  • Zaragoza, Carlos
  • Duro-Sánchez, Santiago
  • Palmas, Francesco
  • Benito-Bueno, Ángela de
  • Socuéllamos, Paula G.
  • Peraza, Diego A.
  • Rodrigues-Díez, Raquel
  • Valenzuela, Carmen
  • Dalli, Jesmond
  • Salaices, Mercedes
  • Briones, Ana M.
[Background]: Resolution of inflammation is orchestrated by specialized proresolving lipid mediators (SPMs), and this would be impaired in some cardiovascular diseases. Among SPMs, resolvins (Rv) have beneficial effects in cardiovascular pathologies, but little is known about their effect on cardiovascular damage in hypertension., [Methods:]: Aorta, small mesenteric arteries, heart, and peritoneal macrophages were taken from C57BL/6J mice, infused or not with angiotensin II (AngII; 1.44 mg/kg/day, 14 days) in presence or absence of resolvin D2 (RvD2) (100 ng/mice, every second day) starting 1 day before or 7 days after AngII infusion., [Results]: Enzymes and receptors involved in SPMs biosynthesis and signaling were increased in aorta or heart from AngII-infused mice. We also observed a differential regulation of SPMs in heart from these mice. Preventive treatment with RvD2 partially avoided AngII-induced hypertension and protected the heart and large and small vessels against functional and structural alterations induced by AngII. RvD2 increased the availability of vasoprotective factors, modified SPMs profile, decreased cardiovascular fibrosis, and increased the infiltration of pro-resolving macrophages. When administered in hypertensive animals with established cardiovascular damage, RvD2 partially improved cardiovascular function and structure, decreased fibrosis, reduced the infiltration of neutrophils, and shifted macrophage phenotype toward a pro-resolving phenotype., [Conclusions]: There is a disbalance between proinflammatory and resolution mediators in hypertension. RvD2 protects cardiovascular function and structure when administered before and after the development of hypertension by modulating vascular factors, fibrosis and inflammation. Activating resolution mechanisms by treatment with RvD2 may represent a novel therapeutic strategy for the treatment of hypertensive cardiovascular disease., This work is supported by SAF2016-80305P (to M. Salaices and A.M. Briones), SAF2016-75021-R (to C. Valenzuela) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”; PID2020-116498RB-I00 (to A.M. Briones), PID2019-104366RB-C21 (to C. Valenzuela) funded by MCIN/AEI/10.13039/501100011033, Grant from Comunidad de Madrid (CM) (B2017/BMD-3676 AORTASANA) FEDER— way to build Europe (to M. Salaices); Grant of the Instituto de Salud Carlos III PI21/01048 (to C. Rodríguez); Grant of Consejo Superior de Investigaciones Cientificas: 2019AEP148 (to C. Valenzuela). The study has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement no. 954798 (to A.M. Briones). R. Rodrigues-Diez was supported by a Juan de la Cierva contract (IJCI-2017-31399). A. de Benito-Bueno is funded by the FPI (BES-2017-080184); P.G. Socuellamos is funded by the FPU (FPU17/02731). J. Dalli is supported by funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant no: 677542) and the Barts Charity (grant no: MGU0343)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Sigma-1 receptor modulation fine-tunes KV1.5 channels and impacts pulmonary vascular function

  • Vera-Zambrano, Alba
  • Baena-Nuevo, M.
  • Rinné, Susanne
  • Villegas-Esguevillas, Marta
  • Barreira, Bianca
  • Telli, Gokcen
  • Benito-Bueno, Ángela de
  • Blázquez, J. A.
  • Climent, Belén
  • Pérez-Vizcaíno, Francisco
  • Valenzuela, Carmen
  • Decher, Niels
  • González, Teresa
  • Cogolludo, Angel
KV1.5 channels are key players in the regulation of vascular tone and atrial excitability and their impairment is associated with cardiovascular diseases including pulmonary arterial hypertension (PAH) and atrial fibrillation (AF). Unfortunately, pharmacological strategies to improve KV1.5 channel function are missing. Herein, we aimed to study whether the chaperone sigma-1 receptor (S1R) is able to regulate these channels and represent a new strategy to enhance their function. By using different electrophysiological and molecular techniques in X. laevis oocytes and HEK293 cells, we demonstrate that S1R physically interacts with KV1.5 channels and regulate their expression and function. S1R induced a bimodal regulation of KV1.5 channel expression/activity, increasing it at low concentrations and decreasing it at high concentrations. Of note, S1R agonists (PRE084 and SKF10047) increased, whereas the S1R antagonist BD1047 decreased, KV1.5 expression and activity. Moreover, PRE084 markedly increased KV1.5 currents in pulmonary artery smooth muscle cells and attenuated vasoconstriction and proliferation in pulmonary arteries. We also show that both KV1.5 channels and S1R, at mRNA and protein levels, are clearly downregulated in samples from PAH and AF patients. Moreover, the expression of both genes showed a positive correlation. Finally, the ability of PRE084 to increase KV1.5 function was preserved under sustained hypoxic conditions, as an in vitro PAH model. Our study provides insight into the key role of S1R in modulating the expression and activity of KV1.5 channels and highlights the potential role of this chaperone as a novel pharmacological target for pathological conditions associated with KV1.5 channel dysfunction., This work was supported by Ministerio de Ciencia e Inovación [SAF2016-75021-R; PID2019-104366RB-C21 to C.V. and T.G., PID2020-117939RB-I00 to A.C., PID2019-107363RB-I00 to F.P.V.]; by CIBERCV, by Instituto de Salud Carlos III [CB/11/00222 to C.V.], by CSIC [PIE201820E104; 2019AEP148 to C.V.]. BES-2017-080184 (to A.B.-B.), funded by MCIN/AEI/ 10.13039/501100011033 and by “ESF Investing in your future” funded by Ministerio de Ciencia e Innovación. A.V.-Z., M.B.-N., A.B.-B. and M.V-E. was awarded with predoctoral fellowships: FPI-UAM, CSIC, FPI and FPU predoctoral contracts, respectively. A.V.-Z. was awarded with a Short-term fellowship from the European Molecular Biology Organization (EMBO)., Peer reviewed